# OnCo record alk-positive-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/alk-positive-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "alk-positive-nsclc" ;
  schema:name "ALK-positive non-small-cell lung cancer"@en ;
  schema:alternateName "ALK-rearranged lung cancer"@en, "ALK fusion NSCLC"@en, "EML4-ALK lung cancer"@en, "ALK+ NSCLC"@en ;
  schema:description "ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."@en ;
  schema:url <https://onco.cc/cancers/alk-positive-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase> ;
  schema:citation <https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/ensartinib/>, <https://onco.cc/drugs/iruplinalkib/>, <https://onco.cc/drugs/neladalkib/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/nuvalent/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/alex/>, <https://onco.cc/trials/alta-1l/>, <https://onco.cc/trials/crown/>, <https://onco.cc/trials/alina/>, <https://onco.cc/trials/alkove-1/> ;
  onco:people <https://onco.cc/people/solomon-benjamin/>, <https://onco.cc/people/ross-camidge/>, <https://onco.cc/people/solange-peters/>, <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/ahn-myung-ju/>, <https://onco.cc/people/wu-yi-long/>, <https://onco.cc/people/justin-gainor/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-crown-nejm-2020/> ;
  onco:pipeline <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/drugs/iruplinalkib/>, <https://onco.cc/drugs/ensartinib/>, <https://onco.cc/ideas/idea-bio1-ctdna-adaptive-tki/> ;
  onco:standardOfCare <https://onco.cc/drugs/alectinib/>, <https://onco.cc/trials/alex/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/trials/alta-1l/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/crown/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/trials/alina/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/wbrt/> .